Categories
Change Password!
Reset Password!
Given the chronic and relapsing nature of acne vulgaris, two 6-month clinical studies were designed to explore the long-term efficacy, safety, and tolerability of clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB)—the only Food and Drug Administration (FDA) approved triple-combination topical therapy for acne.
Triple-combination CAB gel demonstrates strong long-term efficacy and good tolerability for moderate-to-severe acne over 6 months.
Given the chronic and relapsing nature of acne vulgaris, two 6-month clinical studies were designed to explore the long-term efficacy, safety, and tolerability of clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB)—the only Food and Drug Administration (FDA) approved triple-combination topical therapy for acne. The studies also evaluated its impact on acne scarring, post-inflammatory hyperpigmentation (PIH), and post-inflammatory erythema (PIE) in patients with moderate-to-severe acne.
The studies enrolled 50 participants (aged 12 years or older) diagnosed with moderate-to-severe acne, defined by an Investigator’s Global Assessment (IGA) score of 3 or 4. Clinical endpoints included changes from baseline in IGA score and counts of inflammatory and noninflammatory lesions. Additional assessments evaluated skin appearance parameters, including dryness, PIH, PIE, and acne-related scarring. Safety and tolerability outcomes were monitored through reports of adverse events and local skin reactions like redness, itching, burning, and swelling.
The results demonstrated the following findings after 24 weeks of treatment:
CAB triple-combination gel delivered sustained clinical benefits over 6 months in patients with moderate-to-severe acne. The treatment substantially reduced inflammatory and noninflammatory lesions while improving acne-related skin changes, including scarring and dyspigmentation. Overall, the therapy showed consistent efficacy with good tolerability, supporting its use as a long-term topical option for acne management.
Journal of Dermatological Treatment
Long-term efficacy and tolerability of clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel for acne: pooled results from two 6-month studies
Zoe D. Draelos et al.
Comments (0)